Synonym
SPDB, SPDB disulfide heterobifunctional cross-linker.
IUPAC/Chemical Name
N-Succinimidyl 4-(2-pyridyldithio)butanoate
InChi Key
JSHOVKSMJRQOGY-UHFFFAOYSA-N
InChi Code
InChI=1S/C13H14N2O4S2/c16-11-6-7-12(17)15(11)19-13(18)5-3-9-20-21-10-4-1-2-8-14-10/h1-2,4,8H,3,5-7,9H2
SMILES Code
O=C(ON1C(CCC1=O)=O)CCCSSC2=NC=CC=C2
Appearance
Fluffy white solid powder
Purity
>95% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Biological target:
SPDB is a glutathione cleavable ADC linker used for the antibody-drug conjugate (ADCs).
|
Solvent |
mg/mL |
mM |
comments |
| Solubility |
| Ethanol |
100.0 |
306.39 |
|
| Ethanol |
100.0 |
306.39 |
|
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.
Preparing Stock Solutions
The following data is based on the
product
molecular weight
326.39
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Raufi A, Ebrahim AS, Al-Katib A. Targeting CD19 in B-cell lymphoma: emerging role of SAR3419. Cancer Manag Res. 2013 Aug 27;5:225-33. doi: 10.2147/CMAR.S45957. PMID: 24023523; PMCID: PMC3767487.
2: Zhao RY, Wilhelm SD, Audette C, Jones G, Leece BA, Lazar AC, Goldmacher VS, Singh R, Kovtun Y, Widdison WC, Lambert JM, Chari RV. Synthesis and evaluation of hydrophilic linkers for antibody-maytansinoid conjugates. J Med Chem. 2011 May 26;54(10):3606-23. doi: 10.1021/jm2002958. Epub 2011 May 4. PMID: 21517041.
3: Kataoka M, Tanaka T, Kohno T, Kajiyama Y. The carboxyl-terminal domain of TraR, a Streptomyces HutC family repressor, functions in oligomerization. J Bacteriol. 2008 Nov;190(21):7164-9. doi: 10.1128/JB.00843-08. Epub 2008 Aug 22. PMID: 18723611; PMCID: PMC2580714.
4: Cumber A, Wawrzynczak E. Enhanced stability of an immunotoxin made with abrin A chain and a hindered disulphide cross-linker. Biochem Soc Trans. 1992 Nov;20(4):312S. doi: 10.1042/bst020312s. PMID: 1486982.
5: Cumber AJ, Westwood JH, Henry RV, Parnell GD, Coles BF, Wawrzynczak EJ. Structural features of the antibody-A chain linkage that influence the activity and stability of ricin A chain immunotoxins. Bioconjug Chem. 1992 Sep- Oct;3(5):397-401. doi: 10.1021/bc00017a007. PMID: 1329989.
6: Wawrzynczak EJ, Zangemeister-Wittke U, Waibel R, Henry RV, Parnell GD, Cumber AJ, Jones M, Stahel RA. Molecular and biological properties of an abrin A chain immunotoxin designed for therapy of human small cell lung cancer. Br J Cancer. 1992 Aug;66(2):361-6. doi: 10.1038/bjc.1992.271. PMID: 1323991; PMCID: PMC1977812.
7: Worrell NR, Cumber AJ, Parnell GD, Mirza A, Forrester JA, Ross WC. Effect of linkage variation on pharmacokinetics of ricin A chain-antibody conjugates in normal rats. Anticancer Drug Des. 1986 Nov;1(3):179-88. PMID: 3502450.
